Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 17/20 | 0.56 |
| ▸ | MMP2 | P08253 | 16/20 | 0.56 |
| ▸ | MMP1 | P03956 | 14/20 | 0.56 |
| ▸ | MMP9 | P14780 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7622435 | 0.84 | CTSC (0.42) | — | |
| SCHEMBL3217867 | 0.84 | CTSC (0.42) | — | |
| SCHEMBL7644948 | 0.81 | MMP3 (0.43) | MMP3MMP2MMP1MMP9 | |
| SCHEMBL7644955 | 0.81 | MMP3 (0.43) | MMP3MMP2MMP1MMP9 | |
| SCHEMBL7620530 | 0.81 | METAP2 (0.41) | MMP3MMP2MMP1 | |
| SCHEMBL3210794 | 0.81 | METAP2 (0.41) | MMP3MMP2MMP1 | |
| SCHEMBL3221055 | 0.78 | F2RL1 (0.47) | MMP3MMP2MMP1 | |
| SCHEMBL21794975 | 0.77 | KMT2A (0.50) | MMP2 | |
| SCHEMBL30799721 | 0.75 | LTA4H (0.47) | MMP3MMP2MMP1 | |
| SCHEMBL7643594 | 0.74 | KMT2A (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | claimed |
| US-7683097-B2 | Topoisomerase inhibitors | Propharmacon Inc. (US) | 2010-03-23 | — | — | US | disclosed |
| US-20070004701-A1 | Topoisomerase inhibitors | PROPHARMACON, INC. (US) | 2007-01-04 | — | — | US | disclosed |
| WO-2006022955-A2 | TOPOISOMERASE INHIBITORS | PROPHARMACON, INC. (US) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070004701-A1 | Topoisomerase inhibitors | TOP1, TOP2A, TOP2B | MMP3 753/4885MMP2 2089/4885MMP1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.